patients with cancer to determine whether there are alterations in gene expression and/ or mutations in the genes encoding SETD6 or GLP and whether there are changes in the acetylation or methylation of Lys310 and/or phosphorylation of Ser311. All these analyses would help establish the pathway identified here as a potential new source of therapeutic targets in the treatment of cancer and inflammatory diseases.
at least one histone demethylase is promoted, and another in which RelA itself is methylated, thus recruiting GLP, which is antagonized by TNF-activated PKC-ζ.
Like every breakthrough, these new findings solve many mysteries but also raise several questions. For example, what is the subunit composition of the NF-κB complex that contains methylated RelA at the chromatin? Is there a methylated RelA-RelA homodimer or is it in fact a p50-RelA heterodimer? Is this mechanism applicable to all κB-dependent genes or just those with a more closed promoter conformation? Published results suggest that PKC-ζ directly phosphorylates IKKβ in vitro 11 and that PKC-ζ is required for activation of IKKβ in vivo 6 . It will be important to define the cell types in which PKC-ζ acts upstream of IKKβ and those in which it controls RelA transcriptional activity in vivo. Knock-in mouse lines expressing loss-of-function mutations of the sequence encoding Lys310 and Ser311 would help identify the physiological relevance of these modifications, as well as their importance in various diseases to which NF-κB has been linked. In this context, it will be of great interest to analyze samples from human that phosphorylation of Ser311 by PKC-ζ in response to TNF stimulation does in fact lead to displacement of GLP from RelA and therefore to more transcription of κB-dependent genes. Consistent with published results 6 , Levy et al. find that PKC-ζ-deficient cells have lower production of inflammatory cytokines 2 . Therefore, phosphorylation of RelA at Ser311 by PKC-ζ, in addition to favoring histone acetylation by allowing the recruitment of CBP, also inhibits histone methylation by preventing the interaction of GLP with RelA. This finding highlights the importance of the 'hot spot' at positions 310-311 and the relevance of PKC-ζ in its control (Fig. 1) . Interestingly, the regulation of histone methylation by NF-κB has been shown before to also occur as a consequence of activation of this transcription factor. Studies have shown that JMJD3, which demethylates histone H3 at Lys27, is expressed in macrophages activated by lipopolysaccharide 10 . It is believed that this enzyme, by erasing a critical histone mark, controls macrophage differentiation during chronic inflammation 10 . Therefore, a model emerges whereby histone-methylation interaction in NF-κB signaling takes place by two mechanisms: one in which the synthesis of Maruyama et al. now show that another TGF-β-dependent molecular mechanism is involved in Foxp3 expression. They examine the development of CD4 + Foxp3 + T reg cells and show that Foxp3 expression is regulated by cooperation of E2A, Id3 and GATA-3. Not only is Foxp3-dependent T reg cell development impaired in Id3 -/-mice but also their development of T H 17 cells is greater. As Foxp3 inhibits RORγt function 2 , T H 17 cells may be more abundant in these mice as a consequence of the downmodulation of Foxp3 expression. Surprisingly, Rorc expression is also regulated by E2A. Together these results indicate that T H 17 development is regulated by a balance the transcription factor GATA-3 act together in the regulation of Foxp3 expression 1 .
T reg cells suppress excessive immune responses and contribute to the prevention of autoimmune disease caused by potentially hazardous self-reactive T cells. Studies have also shown greater activity of T reg cells associated with tumors. Many laboratories have concentrated on identifying the molecular features of Foxp3 expression. An emerging picture is that Foxp3 expression is controlled by four defined regulatory regions, and indeed the binding of many transcription factors in these regions has already been identified (Fig. 1) . Notably, the activity of most of the transcription factors identified at present is induced by signaling through either the TCR or cytokine receptors, including the receptor for TGF-β. These transcription factors have cooperative activities that are able to induce and maintain Foxp3 expression. In addition, transcription factors The molecular mechanisms that control T reg and T H 17 development and the precise role of transforming growth factor-b in this process are complex and imperfectly understood. New findings indicate that the helix-loop-helix proteins E2A and Id3 are also critically involved in some of these processes. The involvement of multiple transcription factors in Foxp3 expression patterns is now well established. Notably, Foxp3 expression is regulated by both positive and negative cooperative processes, which identifies yet another characterize each regulatory region 8 . Although c-Rel homodimers bind to the CNS3 region, typical enhancer activity is not detected by Foxp3-luciferase reporter assays 8 , unlike that seen with the enhancer 1 region 6 and enhancer 2 region 9 . The CNS3 region seems to be responsible for remodeling of the Foxp3 locus. Studies of the enhancer 1 region have shown that Smad3 and the transcription factor NFAT act together to induce its activity 6 . This enhancer seems to have an important role in the development of induced T reg cells via signals through the TCR and receptor for TGF-β. Enhancer 1 activity has been further shown to involve binding of the transcription activator AP-1 and transcription factor RAR 10 . The activity of enhancer 2 is regulated positively by the transcription factors CREB-ATF, STAT5, Foxo1 and Foxo3 but negatively by STAT3. This enhancer seems to maintain Foxp3 expression. In the Foxp3 promoter region, E2A, AP-1, NFAT, Sp1, STAT1, Foxo1, Foxo3, RUNX1, RUNX3 and c-Rel bind and positively regulate Foxp3 expression. However, Id3 and GATA-3 function as negative regulators.
Maruyama and colleagues highlight the cooperative interactions among E2A, Id3 and GATA-3 that help regulate Foxp3 expression. This complexity suggests that although each regulatory region seems to have its own special role, transcription factors at these regulatory regions need to act together with each other for full Foxp3 expression. Indeed, enhancer 1 activity is much lower after individual mutation of the binding region for each transcription factor (AP-1, RAR, NFAT or Smad3) 6, 10 , which suggests that each cooperates in the induction and maintenance of Foxp3 expression. Foxp3 promoter activity is also substantially upregulated by enhancer 1 (ref. 6 ) and enhancer 2 (ref. 9) . Transcription factors on the promoter and enhancers clearly influence each other's activity. of E2A and Id3 activity, along with Foxp3-dependent and Foxp3-independent actions.
E2A is a member of the E2A protein family, which includes E47 and E12 and is composed of important factors in the regulation of many developmental pathways 3 . Maruyama et al. observe enrichment of E2A at the Foxp3 promoter in cells stimulated with TCR plus TGF-β and also in a Foxp3-luciferase reporter assay. Id3 contains an helix-loop-helix domain that can dimerize with E2A proteins but also is known to be able to inhibit DNA binding because of its lack of a basic region 3 . Because of the inhibitory functions of Foxp3 in differentiation, Foxp3 expression might be predicted to be upregulated in the absence of Id3; however, Maruyama et al. find that Foxp3 expression is lower in Id3 -/-mice. At the same time, GATA-3 mediates the inhibition of Foxp3 expression in cooperation with E2A and Id3. Notably, the activity of both the Foxp3 and Il4 promoters is upregulated by E2A. Gata3 expression is induced in Id3 -/-mice by signaling through the IL-4 receptor, with IL-4 being upregulated by E2A because of absence of the inhibitory protein Id3. GATA-3 is a key transcription factor for the development of T helper type 2 cells and also functions as a negative regulator of Foxp3 expression 4 . Indeed, binding of GATA-3 to the Foxp3 promoter is enhanced in Id3 -/-mice, and, consequently, Foxp3 expression is then down-modulated. Foxp3 expression is therefore regulated by an intricate balance of E2A-Id3 and activated signal transducers Smad2 and Smad3, because the regulation of Id3 by TGF-β is itself directly mediated by Smad activation 3 .
The findings noted above are relevant to previously published observations. For example, mice doubly deficient in Smad2 and Smad3 show considerably inhibited Foxp3 expression relative to that of mice singly deficient in Smad3 (ref. 5). As Smad3 binds to enhancer 1 of Foxp3 and regulates Foxp3 expression 6 , the greater down-modulation of Foxp3 expression in mice doubly deficient in Smad2 andSmad3 may occur via inactivation of Id3. Notchmediated Foxp3 expression has also been studied through the use of pharmacological inhibitors of the Notch pathway (such as γ-secretase inhibitor) 7 . It is therefore possible that Notch also regulates Foxp3 expression via E2A and Id3, because Notch signaling is able to modulate the transcriptional activity of E2A 3 .
The regulatory regions for Foxp3 expression consist of a promoter, two enhancers (1 and 2) and a conserved noncoding sequence region (CNS3) containing a binding site for the c-Rel subunit of the transcription factor NF-κB (Fig. 1) . Mice deficient in enhancer 1 (CNS1), enhancer 2 (CNS2) or CNS3 have been used to
